Financhill
Back

Lineage Cell Therapeutics, Inc. Stock Price Chart

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
47

LCTX
Lineage Cell Therapeutics, Inc.

Last Price:
$1.69
Seasonality Move:
11.05%

7 Day Trial

ALL ACCESS PASS

$ 7
  • The current trend is moderately bearish and LCTX is experiencing slight selling pressure.

Lineage Cell Therapeutics, Inc. Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 1.73 Sell
20-day SMA: 1.72 Sell
50-day SMA: 1.74 Sell
200-day SMA: 1.1 Buy
8-day EMA: 1.73 Sell
20-day EMA: 1.72 Sell
50-day EMA: 1.56 Buy
200-day EMA: 0.76 Buy

Lineage Cell Therapeutics, Inc. Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): 0.02 Buy
Relative Strength Index (14 RSI): 46.3 Sell
Chaikin Money Flow: -1199525 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (1.68 - 1.78) Sell
Bollinger Bands (100): (1.25 - 1.81) Buy

Lineage Cell Therapeutics, Inc. Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Lineage Cell Therapeutics, Inc. Stock

Is Lineage Cell Therapeutics, Inc. Stock a Buy?

LCTX Technical Analysis vs Fundamental Analysis

Sell
47
Lineage Cell Therapeutics, Inc. (LCTX) is a Sell

Is Lineage Cell Therapeutics, Inc. a Buy or a Sell?

Lineage Cell Therapeutics, Inc. Stock Info

Market Cap:
387M
Price in USD:
1.68
Share Volume:
4.1M

Lineage Cell Therapeutics, Inc. 52-Week Range

52-Week High:
2.09
52-Week Low:
0.37
Sell
47
Lineage Cell Therapeutics, Inc. (LCTX) is a Sell

Lineage Cell Therapeutics, Inc. Share Price Forecast

Is Lineage Cell Therapeutics, Inc. Stock a Buy?

Fundamental Analysis of Lineage Cell Therapeutics, Inc.

Is Lineage Cell Therapeutics, Inc. a good investment?

  • Analysts estimate an earnings decrease this quarter of $0.01 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.18 per share, and an increase next year of $0.23 per share.

Technical Analysis of Lineage Cell Therapeutics, Inc.

Should I short Lineage Cell Therapeutics, Inc. stock?

* Lineage Cell Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.